Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.58 |
| ▸ | CD74 | P04233 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948413 | 0.90 | MIF (0.59) | MIFCD74KMT2AMEN1POLB | |
| SCHEMBL13962153 | 0.82 | MIF (0.39) | MIF | |
| SCHEMBL30615684 | 0.82 | NPC1 (0.58) | KMT2AALDH1A1 | |
| SCHEMBL28500980 | 0.82 | NPC1 (0.58) | KMT2AALDH1A1 | |
| SCHEMBL24973917 | 0.82 | MIF (0.54) | MIFCD74KMT2AMEN1POLB | |
| SCHEMBL13341017 | 0.82 | PPARG (0.46) | MIFPOLB | |
| SCHEMBL13367743 | 0.80 | MIF (0.66) | MIFCD74PTGS2KMT2AMEN1 | |
| SCHEMBL30195005 | 0.78 | TSHR (0.64) | MIFALDH1A1 | |
| SCHEMBL17766397 | 0.78 | KMO (0.41) | MIFCD74 | |
| SCHEMBL14518249 | 0.76 | MIF (0.65) | MIFCD74PTGS2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993585-B2 | Cyclic amine substituted pyrimidinediamines as PKC inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130486-A1 | CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS | PRKCH, PKD2, PRKCQ | MIF 4047/4885CD74 3972/4885PTGS2 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.